No Data
Sinolink: Several central and state-owned enterprises in the building materials sector, including Beixin and Kaisheng, have released incentive plans that emphasize the direction of Market Cap management.
From the action plans of state-owned and centrally administered enterprises that are being progressively implemented, the overall process has accelerated, reflecting the confidence of central enterprises in high-quality development and operational capabilities, and it is expected to play a leading role in specific segments of the Industry.
Shandong Pharmaceutical Glass (600529.SH): The indirect controlling shareholder may change.
Shandong Pharmaceutical Glass (600529.SH) announced that on December 30, 2024, the company received notice from its controlling Shareholder Shan...
While Shareholders of Shandong Pharmaceutical GlassLtd (SHSE:600529) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown
Debon Securities: The scale of borosilicate pharmaceutical glass is continuously expanding. Pay attention to the improvement in profitability within the industry as costs decline.
National centralized procurement promotes the adoption of pharmaceuticals with medium borosilicate packaging, expanding the market size of medium borosilicate pharmaceutical glass.
Shandong pharmaceutical glass (600529.SH): the company's production line is primarily running at full capacity.
On November 27, Glonghui reported that shandong pharmaceutical glass (600529.SH) stated on the investor interaction platform that its production lines are operating at near full capacity; the existing production capacity of pre-filled products can meet market demand, and the delay of the project to expand the annual production capacity of 0.56 billion pre-filled syringes does not have a substantial impact on the company’s production and performance.
Shandong Pharmaceutical Glass (600529.SH): The fundraising project "Annual production of 0.56 billion pre-filled syringe expansion and transformation project" has been postponed to December 31, 2025.
On November 25, Gelonghui reported that shandong pharmaceutical glass (600529.SH) announced that the company's 15th meeting of the 10th board of directors and the 13th meeting of the 10th board of supervisors were held on November 25, 2024, reviewing and passing the proposal to postpone the "Annual production of 0.56 billion pre-filled syringe expansion and transformation project". It was agreed that under the premise of no changes to the subject, method, purpose, and scale of the fundraising investment project, the completion time of the fundraising project "Annual production of 0.56 billion pre-filled syringe expansion and transformation project" will be changed to December 31, 2024.
No Data
